Clinical trial
Effect Of Rilapladib (SB-659032) On Platelet Aggregation
NCT00387257 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00387257 |
|---|---|
| Title | Effect Of Rilapladib (SB-659032) On Platelet Aggregation |
| Official title | A Double Blind, Placebo Controlled, Parallel Study to Evaluate Effects of Repeat Doses of Rilapladib on Platelet Aggregation in Healthy Male Volunteers |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy Subjects, Atherosclerosis |
| Intervention type | Drug |
| Interventions | Rilapladib (SB-659032) |
| Enrollment | 58 |
| Start date | Oct 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Oct 12, 2006 |
| Last update posted | Apr 15, 2015 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: